The OncoAlert🚨Newsletter, EVERY WEEK! This week Covering April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TALAPRO2 in #ProstateCancer ✅SBRT☢️ & IO in #KidneyCancer ✅ Challenges in #SCLC heterogeneity &Plasticity🫁

ARE YOU READY?🏃‍♀️ #OncoAlert5k @ #ASCO25 🏃‍♂️ SIGN UP NOW OPEN & Required‼️ 👉 oncoalert.m-pages.com/P3LU6F/the-onc… MAY 31, 2025 at 7am☀️in front of McCormick Place🚨 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González

📣ESMO Living Guidelines on Metastatic Breast Cancer: 👉Just updated with the latest recommendations and algorithms in an interactive format. 🔗ow.ly/loX750VBoN6 #ClinicalPracticeGuideline

NEWS FROM INDUSTRY Source AstraZeneca astrazeneca.com/media-centre/p… The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically

We’re sharing topline results from our Phase 3 ASCENT-04 study for people living with metastatic triple-negative breast cancer. For individuals with #TNBC, these results potentially offer a new pathway that may redefine their treatment options. Read more: gilead.inc/42KdhSV

NEWS FROM INDUSTRY Source Gilead Gilead announces positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial, showing that the combination of sacituzumab govitecan-hziy and pembrolizumab improved PFS🆚the standard regimen of pembrolizumab plus chemotherapy in patients with

Hi everyone - my previous account Biagio Ricciuti, MD PhD was compromised and is no longer under my control. This is my new official profile Biagio Ricciuti, MD, PhD. I’d be grateful if you could kindly help spread the word. OncoAlert Dana-Farber Dana-Farber News

Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors ESMO - Eur. Oncology

Sara Tolaney from Dana-Farber’s Breast Oncology Center reviews a rainbow of novel treatment options becoming available for HR+/HER2- mBC over the past yrs (& many upcoming approvals over the next year). New challenges: optimizing their sequence & selecting control arms #ESMOAmbassadors #ESMOBreast25

Top 10 Breast Cancer Trials to Watch at #ASCO25 Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC! 1️⃣ DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA] 2️⃣ ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA] 3️⃣ SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA] 4️⃣

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB

NEWS FROM INDUSTRY: Source Business Wire Update ASCENT-03 The Phase 3 ASCENT-03 trial sees sacituzumab govitecan-hziy improves progression-free survival compared to standard chemotherapy in patients with first-line metastatic triple-negative #BreastCancer (m #TNBC ) who are

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at ASCO HERE in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB +PERTUZUMAB

The #OncoAlert5k at #ASCO25 is Tomorrow Saturday May 31, 2025 at 7 AM Meeting in the FRONT of the McCormick by the LARGE ASCO Letters A Great and Healthy way to start your Meeting!! Recommend getting there a little bit earlier 6:45 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa

An honor to present our OncoAlert #BreastCancer Faculty Erika Hamilton, MD 🇺🇸Who just presented the Results of VERITAC-2 at #ASCO25 Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative

An honor to Present our OncoAlert 🚨#BreastCancer Faculty Sara Tolaney 🇺🇸 from Dana-Farber who just presented ASCENT-04 at #ASCO25 Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1-positive advanced

Dear Colleagues at #ASCO25 You are warmly invited to watch the Top Trials of the Year, presented by some of the world’s leading experts. All sessions are free and available on demand JUST CLICK AND WATCH ⭐ GU Oncology buff.ly/3hkYYG6 ⭐ #BreastCancer

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer